Brimonidine is a selective alpha-2 adrenergic agonist used topically to reduce intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. It lowers IOP by 15-20% through dual mechanisms: reducing aqueous humor production and increasing uveoscleral outflow. It is commonly used as second-line therapy or adjunctive to prostaglandin analogs, and is available in fixed combination with timolol (Combigan). A lower concentration formulation (Alphagan P 0.1%) with purite preservative has improved tolerability.
Dual mechanism: reduces aqueous production and increases uveoscleral outflow
Potential retinal neuroprotective properties
No significant effect on pupil size at standard doses
Available in fixed-combination with timolol for convenience4,5
What to watch for
Ocular allergy/allergic conjunctivitis (up to 25%, most common reason for discontinuation)
Dry mouth
Ocular hyperemia
Known hypersensitivity to brimonidine or any component1,2
Neonates and infants under 2 years of age (risk of severe CNS depression, apnea, hypotension, hypothermia)
The bottom line
Evidence rating strong. Most-documented uses: dual mechanism: reduces aqueous production and increases uveoscleral outflow, potential retinal neuroprotective properties, no significant effect on pupil size at standard doses. 10 sources indexed (2000–2025), with 2 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Selectively activates alpha-2 adrenergic receptors in the ciliary body, which reduces aqueous humor production via decreased cyclic AMP. Simultaneously increases uveoscleral outflow, providing a dual mechanism for IOP reduction. Also has potential neuroprotective properties for retinal ganglion cells by reducing apoptosis and increasing expression of brain-derived neurotrophic factor (BDNF), though clinical significance is under investigation.
Class
Alpha-2 Agonist / Ophthalmologic
Dosing
Dosing & protocol.
Common range
One drop of 0.1-0.2% solution in affected eye(s) three times daily, approximately 8 hours apart (as prescribed by your physician)
Recommended form
Ophthalmic solution; Alphagan P 0.1% (with purite preservative) preferred over 0.2% (with BAK) for better tolerability
Topical ophthalmic application; some systemic absorption occurs. Space at least 5 minutes between instillation of different eye drops. Can cause systemic alpha-2 agonist effects, especially in small children (contraindicated in infants and neonates).5
Safety
Full safety detail.
Side effects
Ocular allergy/allergic conjunctivitis (up to 25%, most common reason for discontinuation)
Dry mouth
Ocular hyperemia
Burning and stinging
Fatigue and drowsiness (systemic)
Foreign body sensation
Follicular conjunctivitis
Contraindications
Known hypersensitivity to brimonidine or any component1,2
Neonates and infants under 2 years of age (risk of severe CNS depression, apnea, hypotension, hypothermia)
Concurrent use with MAO inhibitors
Severe cardiovascular disease
Children ages 2-7 (use with caution; higher risk of CNS depression)
Brimonidine eye drops can cause systemic alpha-2 agonist effects in some people, including fatigue, somnolence, low blood pressure, and dizziness. Alcohol independently causes sedation, psychomotor impairment, and can worsen orthostatic symptoms. Together they can make driving, nighttime walking, or standing quickly less safe, especially in older adults or those using other sedatives.
Recommendation: Limit alcohol when starting brimonidine or after dose changes, and avoid driving if you feel drowsy or lightheaded. Use punctal occlusion after eye drops to reduce systemic absorption. Contact your prescriber if alcohol reliably triggers marked fatigue, faintness, slow breathing, or confusion while using brimonidine.
THC-dominant cannabis can add to brimonidine-related drowsiness, slowed reactions, dizziness, or blood-pressure symptoms. Brimonidine has documented systemic CNS and cardiovascular adverse effects in susceptible users, while THC acutely impairs psychomotor and driving-related performance. The combination is most concerning with new brimonidine use, high-THC products, older age, or other sedating medicines.
Recommendation: Avoid THC-dominant cannabis when you need to drive or do safety-sensitive tasks after using brimonidine. Use punctal occlusion with eye drops to reduce systemic exposure. If you notice marked sleepiness, dizziness, fainting, or confusion, stop cannabis use and contact your prescriber.
Cantor LB, Liu CC, Batoosingh AL et al.. Safety and tolerability of brimonidine purite 0.1% and brimonidine purite 0.15%: a meta-analysis of two phase 3 studies. Current medical research and opinion. 2009
Loon SC, Liew G, Fung A et al.. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. Clinical & experimental ophthalmology. 2008
Einarson TR, Kulin NA, Tingey D et al.. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma. Clinical therapeutics. 2000
Kim M, Lee CK, Shin J et al.. Comparison of Efficacy and Ocular Surface Assessment Between Preserved and Preservative-Free Brimonidine/Timolol Fixed-Combination Eye Drops in Glaucoma Patients: A Parallel-Grouped, Randomized Trial. Journal of clinical medicine. 2025
Tanihara H, Yamamoto T, Aihara M et al.. Ripasudil-Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials. American journal of ophthalmology. 2023
Freeman WR, Bandello F, Souied E et al.. Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration. Ophthalmology. Retina. 2023
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Brimonidine in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack